What are the key business segments of Johnson & Johnson during this period?

Based on general knowledge of Johnson & Johnson during the mid-1990s, its primary business segments typically included Pharmaceuticals, Medical Devices and Diagnostics, and Consumer Products. The full 10-Q filing would provide specific details on the performance of each segment.

Where can I find the actual financial statements and detailed analysis within this filing?

The provided text is a directory listing of the SEC filing. The actual financial statements (Consolidated Balance Sheets, Statements of Operations, Statements of Cash Flows), along with Management's Discussion and Analysis, would be contained within the full .txt or HTML document of the 10-Q filing, accessible through the SEC's EDGAR database or financial data providers.

What were the major market trends or challenges affecting Johnson & Johnson in late 1995?

In late 1995, the healthcare industry was likely experiencing trends such as increasing healthcare cost containment pressures, evolving regulatory environments, and ongoing consolidation. Johnson & Johnson, with its diverse portfolio, would have been navigating these factors across its different business units. Specific challenges and opportunities would be detailed in the 'Management's Discussion and Analysis' section of the full filing.

Does this filing mention any significant acquisitions or divestitures?

The provided directory listing does not contain information about specific acquisitions or divestitures. This information would typically be found in the 'Notes to Consolidated Financial Statements' or within the 'Management's Discussion and Analysis' of the full 10-Q report if any material events occurred during the quarter.

JNJ 10-Q Filed Nov 13, 1995

Summary

This 10-Q filing from Johnson & Johnson, for the period ending September 30, 1995, provides a snapshot of the company's financial performance and operational status. While the provided text is a directory listing of the filing and does not contain the actual financial statements, it indicates that JNJ was actively reporting to the SEC. Investors would typically look to the detailed financial tables within the full filing to assess revenue growth, profitability, balance sheet strength, and cash flow generation across its diverse business segments (pharmaceuticals, medical devices, and consumer products). The filing would also detail any significant business developments, risks, or legal proceedings that could impact the company's future outlook. As a leading healthcare conglomerate, JNJ's performance in this period would be crucial for understanding its competitive position and ability to navigate the evolving healthcare landscape of the mid-1990s. Investors would pay close attention to the segment-specific performance to identify areas of strength and potential weakness, as well as any commentary on strategic initiatives or market trends that management believes are influencing the business. The absence of specific financial data in this excerpt means a deep dive into the numbers is not possible, but the filing's existence confirms JNJ's commitment to regulatory transparency.

Key Highlights

1Johnson & Johnson filed its 10-Q Quarterly Report on November 13, 1995, for the period ending September 30, 1995.
2The filing falls within the company's reporting cycle, indicating ongoing financial disclosure to the SEC.
3As a diversified healthcare company, JNJ operates across pharmaceuticals, medical devices, and consumer health products.
4Investors would typically analyze revenue and profit trends across these segments in the full report.
5The report would provide insights into the company's financial health, operational performance, and strategic direction.
6This filing is a standard disclosure mechanism for publicly traded companies like JNJ.

JOHNSON & JOHNSON Quarterly Report for Q3 Ended Oct 1, 1995

Summary

Key Highlights

Frequently Asked Questions